ACOR
Acorda Therapeutics Inc

Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Market Cap: 4.95 Million
Primary Exchange: NASDAQ
Website: www.acorda.com
Shares Outstanding: 13.3 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.60139084396567
Sector:
Industry:
Ethical Flags

Longest drawdown: 2061 trading days
From: 2015-01-26 To: 2022-06-23
Lowest Point:
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|